

Vermont Fiscal Year Ending June 30, 2025 Assessment

	Child				Adult			
	Prior Assessment Period		Current Assessment Period		Prior Assessment Period		Current Assessment Period	
Vaccine Cost Estimates								
Estimated Non-Flu Vaccine Cost Based on Current CDC Prices		\$ 14,874,170		\$ 17,024,923		\$ 5,956,398		\$ 6,592,087
Estimated Flu Vaccine Cost Based on Current CDC Prices		\$ 900,047		\$ 882,734		\$ 705,700		\$ 648,216
Estimated COVID-19 Vaccine Cost Based on Current CDC Prices		\$ 5,000,000		\$ 2,641,660		\$ 5,000,000		\$ 2,514,560
Total Estimated Vaccine Cost Based on Current CDC Prices		\$ 20,774,216		\$ 20,549,318		\$ 11,662,098		\$ 9,754,863
Provision for Vaccine Cost Increase	0.0%	\$ -	0.0%	\$ -	3.5%	\$ 410,214	3.3%	\$ 326,250
Provision for Vaccine Utilization Increase	0.5%	\$ 103,871	0.5%	\$ 102,747	0.5%	\$ 58,310	0.5%	\$ 48,774
Subtotal Estimated Vaccine Costs		\$ 20,878,087		\$ 20,652,064		\$ 12,130,623		\$ 10,129,887
Awards and Grants		\$ (11,218,077)		\$ (10,685,645)		\$ (323,378)		\$ (338,378)
Total Estimated Vaccine Costs		\$ 9,660,010		\$ 9,966,419		\$ 11,807,245		\$ 9,791,509
Total Administrative and Operating Costs		\$ 469,511		\$ 496,396		\$ 576,215		\$ 494,884
Total Reserves / Working Capital		\$ (848,008)		\$ (3,177,433)		\$ (845,058)		\$ (3,883,715)
Total Assessable Covered Lives Estimate		57,161		56,949		351,506		346,871
Assessment Calculation								
Total Assessment		\$ 9,281,514		\$ 7,285,382		\$ 11,538,401		\$ 6,402,678
Total Assessment Per Covered Life		\$ 162.48		\$ 127.93		\$ 32.88		\$ 18.46
Monthly Assessment Per Covered Life Calculated / % Change		\$ 13.54	-21.3%	\$ 10.66		\$ 2.74	-43.9%	\$ 1.54
Preliminary Projection								
Run Rate Monthly Assessment Per Covered Life		\$ 14.77		\$ 15.31		\$ 2.94		\$ 2.47
Preliminary Assessment projection	0.0%	\$ 14.77	0.0%	\$ 15.31	3.5%	\$ 3.04	3.3%	\$ 2.55
Preliminary Assessment increase		9.07%		43.61%		10.93%		66.03%
Program Metrics								
Administrative and Operational Costs as % of Vaccine Costs		4.86%		4.98%		4.88%		5.05%
CDC Vaccine Costs as % Below Private Purchase Costs				-27.55%				-36.63%

Notes:

Vermont Fiscal Year Ending June 30, 2025 Assessment

Change in Assessment (from 2024 Fiscal Year Ending June 30, 2024 to 2025 Fiscal Year Ending June 30, 2025)

	Child			Adult		
	Cost	PMPM	% Change	Cost	PMPM	% Change
2024 Fiscal Year Ending June 30, 2024	\$9,281,514	\$ 13.54		\$11,538,401	\$ 2.74	
Change In:						
Contribution Enrollees		\$ 0.04	0.3%	\$ 0.03	1.1%	
Estimated Vaccine Cost	\$ (224,898)	\$ (0.33)	-2.4%	\$ (1,907,235)	\$ (0.46)	-16.8%
Stock Separation/ Other Cost	\$ -	\$ -	0.0%	\$ -	\$ -	0.0%
Provision For Vaccine Cost Increase	\$ -	\$ -	0.0%	\$ (83,964)	\$ (0.02)	-0.7%
Provision For Vaccine Utilization Increase	\$ (1,124)	\$ -	0.0%	\$ (9,536)	\$ -	0.0%
Vaccine Waste Allowance	\$ -	\$ -	0.0%	\$ -	\$ -	0.0%
Awards and Grants	\$ 532,432	\$ 0.78	5.8%	\$ (15,000)	\$ -	0.0%
Non-Vaccine Program Benefit Costs	\$ -	\$ -	0.0%	\$ -	\$ -	0.0%
Administrative Costs	\$ 26,884	\$ 0.04	0.3%	\$ (81,331)	\$ (0.02)	-0.7%
Operational Costs	\$ -	\$ -	0.0%	\$ -	\$ -	0.0%
Reserve/Working Capital	\$ (2,329,425)	\$ (3.41)	-25.2%	\$ (3,038,656)	\$ (0.73)	-26.6%
2025 Fiscal Year Ending June 30, 2025	\$7,285,382	\$ 10.66	-21.3%	\$6,402,678	\$ 1.54	-43.8%

Comments

Vermont Fiscal Year Ending June 30, 2025 Assessment

Vaccine Cost Walk Down

	Child			Adult		
	Cost	Doses	Cost/ Dose	Cost	Doses	Cost/ Dose
2024 Fiscal Year Ending June 30, 2024	\$ 20,878,087	267,560	\$ 78.03	\$ 12,130,623	173,650	\$ 69.86
2025 Fiscal Year Ending June 30, 2025 Excluding RSV	\$ 19,648,509	244,680	\$ 80.30	\$ 9,449,162	143,320	\$ 65.93
Change from Prior Period	\$ (1,229,578)	-22,880	\$ 2.27	\$ (2,681,461)	-30,330	\$ (3.93)
Percentage Change from Prior Period	-5.9%	-8.6%	2.9%	-22.1%	-17.5%	-5.6%
<i>Financial Impact excluding RSV</i>	\$ (1,229,578)	\$ (1,837,330)	\$ 607,752	\$ (2,681,461)	\$ (1,999,673)	\$ (681,789)
2025 Fiscal Year Ending June 30, 2025 Excluding RSV	\$ 19,648,509	244,680	\$ 80.30	\$ 9,449,162	143,320	\$ 65.93
RSV	\$ 1,003,555	2,550	\$ 393.55	\$ 680,725	3,500	\$ 194.49
2025 Fiscal Year Ending June 30, 2025 Including RSV	\$ 20,652,064	247,230	\$ 83.53	\$ 10,129,887	146,820	\$ 69.00
Total Change to Prior Year	\$ (226,023)	-20,330	\$ 5.50	\$ (2,000,736)	-26,830	\$ (0.86)
Percentage Change from Prior Year	-1.1%	-7.6%	7.1%	-16.5%	-15.5%	-1.2%

Comments

Vermont Fiscal Year Ending June 30, 2025 Assessment

Comparison to Prior Period

		Cost Per Dose	Doses	Cost
Total Pediatric	Prior Period Projected	\$ 78.03	267,560	\$ 20,878,087
	Current Period Projected	\$ 83.53	247,230	\$ 20,652,064
	Variance	\$ 5.50	-20,330	\$ (226,023)
	% Variance	7.1%	-7.6%	-1.1%
Total Adult	Prior Period Projected	\$ 69.86	173,650	\$ 12,130,623
	Current Period Projected	\$ 69.00	146,820	\$ 10,129,887
	Variance	\$ (0.86)	-26,830	\$ (2,000,736)
	% Variance	-1.2%	-15.5%	-16.5%
Pediatric	Prior Period Projected	\$ 94.88	157,560	\$ 14,948,540
	Current Period Projected	\$ 106.78	160,230	\$ 17,110,048
	Variance	\$ 11.91	2,670	\$ 2,161,507
	% Variance	12.6%	1.7%	14.5%
Adult	Prior Period Projected	\$ 84.12	73,650	\$ 6,195,697
	Current Period Projected	\$ 90.18	76,020	\$ 6,855,770
	Variance	\$ 6.06	2,370	\$ 660,074
	% Variance	7.2%	3.2%	10.7%
Pediatric Flu	Prior Period Projected	\$ 15.08	60,000	\$ 904,547
	Current Period Projected	\$ 17.40	51,000	\$ 887,148
	Variance	\$ 2.32	-9,000	\$ (17,399)
	% Variance	15.4%	-15.0%	-1.9%
Adult Flu	Prior Period Projected	\$ 14.68	50,000	\$ 734,051
	Current Period Projected	\$ 16.27	40,500	\$ 658,974
	Variance	\$ 1.59	-9,500	\$ (75,077)
	% Variance	10.8%	-19.0%	-10.2%
Pediatric COVID-19	Prior Period Projected	\$ 100.50	50,000	\$ 5,025,000
	Current Period Projected	\$ 73.75	36,000	\$ 2,654,868
	Variance	\$ (26.75)	-14,000	\$ (2,370,132)
	% Variance	-26.6%	-28.0%	-47.2%
Adult COVID-19	Prior Period Projected	\$ 104.02	50,000	\$ 5,200,875
	Current Period Projected	\$ 86.31	30,300	\$ 2,615,142
	Variance	\$ (17.71)	-19,700	\$ (2,585,733)
	% Variance	-17.0%	-39.4%	-49.7%

Vermont Fiscal Year Ending June 30, 2025 Assessment

Summary Statistics

	Current Assessment Period										
	Dose Quantity	Vaccine Cost	Private Cost	Projected Private Cost	Stock Separation/ Other Cost	Cost Increase Assumption	Provision for Cost/ Dose Increase	Utilization Increase Assumption	Provision for Utilization Increase	Vaccine Waste Allowance	Projected Vaccine Cost
Total Pediatric	247,230	\$ 20,549,318	\$ 28,364,948	\$ 28,506,772	\$ -	0.0%	\$ -	0.5%	\$ 102,747	\$ -	\$ 20,652,064
Total Adult	146,820	\$ 9,754,863	\$ 15,392,914	\$ 15,985,612	\$ -	3.3%	\$ 326,250	0.5%	\$ 48,774	\$ -	\$ 10,129,887
Pediatric	160,230	\$ 17,024,923	\$ 23,745,068	\$ 23,863,794	\$ -	0.0%	\$ -	0.5%	\$ 85,125	\$ -	\$ 17,110,048
Adult	76,020	\$ 6,592,087	\$ 10,712,344	\$ 11,140,838	\$ -	3.5%	\$ 230,723	0.5%	\$ 32,960	\$ -	\$ 6,855,770
Pediatric Flu	51,000	\$ 882,734	\$ 1,215,879	\$ 1,221,959	\$ -	0.0%	\$ -	0.5%	\$ 4,414	\$ -	\$ 887,148
Adult Flu	40,500	\$ 648,216	\$ 983,570	\$ 999,894	\$ -	1.2%	\$ 7,517	0.5%	\$ 3,241	\$ -	\$ 658,974
Pediatric COVID-19	36,000	\$ 2,641,660	\$ 3,404,000	\$ 3,421,020	\$ -	0.0%	\$ -	0.5%	\$ 13,208	\$ -	\$ 2,654,868
Adult COVID-19	30,300	\$ 2,514,560	\$ 3,697,000	\$ 3,844,880	\$ -	3.5%	\$ 88,010	0.5%	\$ 12,573	\$ -	\$ 2,615,142

	Prior Assessment Period										
	Dose Quantity	Vaccine Cost	Private Cost	Projected Private Cost	Stock Separation/ Other Cost	Cost Increase Assumption	Provision for Cost/ Dose Increase	Utilization Increase Assumption	Provision for Utilization Increase	Vaccine Waste Allowance	Projected Vaccine Cost
Total Pediatric	267,560	\$ 20,774,216	\$ 4,631,250	\$ -	\$ -	0.0%	\$ -	0.5%	\$ 103,871	\$ -	\$ 20,878,087
Total Adult	173,650	\$ 11,662,098	\$ 6,102,000	\$ -	\$ -	3.5%	\$ 410,214	0.5%	\$ 58,310	\$ -	\$ 12,130,623
Pediatric	157,560	\$ 14,874,170	\$ -	\$ -	\$ -	0.0%	\$ -	0.5%	\$ 74,371	\$ -	\$ 14,948,540
Adult	73,650	\$ 5,956,398	\$ -	\$ -	\$ -	3.5%	\$ 209,516	0.5%	\$ 29,782	\$ -	\$ 6,195,697
Pediatric Flu	60,000	\$ 900,047	\$ -	\$ -	\$ -	0.0%	\$ -	0.5%	\$ 4,500	\$ -	\$ 904,547
Adult Flu	50,000	\$ 705,700	\$ -	\$ -	\$ -	3.5%	\$ 24,823	0.5%	\$ 3,529	\$ -	\$ 734,051
Pediatric COVID-19	50,000	\$ 5,000,000	\$ 4,631,250	\$ -	\$ -	0.0%	\$ -	0.5%	\$ 25,000	\$ -	\$ 5,025,000
Adult COVID-19	50,000	\$ 5,000,000	\$ 6,102,000	\$ -	\$ -	3.5%	\$ 175,875	0.5%	\$ 25,000	\$ -	\$ 5,200,875

	CDC Cost to Private Cost %	Difference Between CDC Cost/ Dose and Private Cost/ Dose	Cost Change Due to Price Change	% Change in Cost/ Dose	Change in Dose Quantity	Cost at Prior Year Dose Quantity	Cost Change Due to Dose Change	% Cost Change Due to Dose Change	Total Cost Change
Total Pediatric	-27.6%	\$ (1,835.40)	\$ (635,143)	-3.1%	(20,330)	\$ 20,139,073	\$ 410,245	2.0%	\$ (224,898)
Total Adult	-36.6%	\$ (1,813.66)	\$ (245,260)	-2.1%	(26,830)	\$ 11,416,838	\$ (1,661,975)	-14.6%	\$ (1,907,235)
Pediatric	-28.3%	\$ (1,605.22)	\$ 734,512	4.9%	2,670	\$ 15,608,682	\$ 1,416,241	9.1%	\$ 2,150,754
Adult	-38.5%	\$ (1,468.83)	\$ 611,435	10.3%	2,370	\$ 6,567,833	\$ 24,254	0.4%	\$ 635,689
Pediatric Flu	-27.4%	\$ (36.58)	\$ 15,470	1.7%	(9,000)	\$ 915,516	\$ (32,782)	-3.6%	\$ (17,312)
Adult Flu	-34.1%	\$ (48.24)	\$ (5,660)	-0.8%	(9,500)	\$ 700,040	\$ (51,824)	-7.4%	\$ (57,484)
Pediatric COVID-19	-22.4%	\$ (193.60)	\$ (1,385,125)	-27.7%	(14,000)	\$ 3,614,875	\$ (973,215)	-26.9%	\$ (2,358,340)
Adult COVID-19	-32.0%	\$ (296.58)	\$ (851,035)	-17.0%	(19,700)	\$ 4,148,965	\$ (1,634,405)	-39.4%	\$ (2,485,440)